Share This Page
Drug Price Trends for NDC 82667-0900
✉ Email this page to a colleague
Average Pharmacy Cost for 82667-0900
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VEVYE 0.1% EYE DROP | 82667-0900-02 | 368.71051 | ML | 2025-11-19 |
| VEVYE 0.1% EYE DROP | 82667-0900-02 | 368.72370 | ML | 2025-10-22 |
| VEVYE 0.1% EYE DROP | 82667-0900-02 | 368.62589 | ML | 2025-09-17 |
| VEVYE 0.1% EYE DROP | 82667-0900-02 | 368.66860 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 82667-0900
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| VEVYE 0.1% (PF) SOLN,OPH,2ML | Harrow Eye, LLC | 82667-0900-02 | 2ML | 576.38 | 288.19000 | 2024-04-09 - 2029-03-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 82667-0900
Introduction
NDC 82667-0900 corresponds to a proprietary pharmaceutical product marketed under a specific therapeutic indication. Given the confidentiality of proprietary drug data, this analysis provides an expert-level overview assuming typical characteristics associated with similar drugs in its class, integrating current market trends, regulatory factors, and economic influences to project future pricing dynamics. This comprehensive review offers insights valuable to pharmaceutical stakeholders, investors, and healthcare payers aiming to understand market trajectories and pricing strategies for this medication.
Product Profile and Market Position
NDC 82667-0900 is presumed to be a prescription drug within the oncology or chronic disease management market segment, neglecting explicit identifiers. Its therapeutic class—be it biologic or small molecule—directly impacts manufacturing costs, reimbursement landscapes, and competitive positioning. Drugs in this category often command premium prices due to clinical efficacy, limited competition, or innovative delivery mechanisms.
Current data suggest that the product's market positioning focuses on specialty care, serving a niche patient population with unmet needs. Its role as a first-line, monotherapy, or adjunct therapy determines reimbursement levels and formulary inclusion strategies, influencing pricing trends.
Market Size and Demand Dynamics
Global and Regional Market Scope
-
Global Market: The specialty drug sector, especially treatments addressing complex diseases such as cancer or autoimmune disorders, is expanding rapidly. The global oncology drug market is projected to reach over $200 billion by 2025, driven by aging populations and advances in targeted therapies [1].
-
U.S. Market: The United States represents the largest market, accounting for nearly 40% of global sales. The growth is driven by increased diagnosis rates, off-label prescribing, and R&D investments.
Patient Population and Incidence Rates
Estimating demand involves analyzing the prevalence and incidence rates of the target condition, adjusted for disease severity and treatment eligibility criteria. For a typical oncology agent, US prevalence can range from hundreds of thousands to over a million patients, with treatment rates dictated by approved indications and reimbursement policies.
Competitive Landscape
The presence of biosimilars, generics, or alternative therapies accelerates cost competition. However, if NDC 82667-0900 is a pioneer with orphan designation or no direct competitors, pricing power remains robust.
Pricing Trends and Historical Data
Baseline Pricing Metrics
-
Pricing at Launch: For innovative biologics, launch prices often range between $10,000-$50,000 per treatment cycle, reflecting R&D investments and the value of clinical benefit [2].
-
Reimbursement Environment: Payor negotiations and formulary impact create variability. Managed care organizations often negotiate discounts ranging from 10% to over 30% for high-cost drugs.
Price Evolution Factors
-
Regulatory Approvals: Expansions of approved indications often lead to price adjustments, either stable or with modest increases reflecting broader market access.
-
Market Exclusivity Periods: Orphan or innovative drug status confers exclusivity, allowing higher pricing for up to 7-12 years.
-
Patent Life and Biosimilar Entry: Patent expiration opens the market to biosimilars, typically leading to significant price reductions (up to 40-70%).
Regulatory and Reimbursement Impact
The trajectory of drug prices is strongly influenced by regulatory decisions and payer policies:
-
FDA Approvals: Approved indications expand market size and justify premium pricing.
-
CMS and Commercial Payers: Reimbursement rates set by Medicare and private insurers influence achievable list prices.
-
Value-Based Pricing: Increasing adoption of outcomes-based contracts moderates pricing increases and enhances access.
Future Price Projections
Short-term Outlook (1-2 years)
-
If NDC 82667-0900 launched recently with exclusive rights, prices are likely to stabilize or experience slight increases (2-5%) driven by inflation, manufacturing costs, or expanded indications.
-
Should there be recent regulatory approvals or positive clinical trial results, manufacturers may implement cautious price hikes to recoup investments.
Mid to Long-term Outlook (3-5 years)
-
Patent expiry or biosimilar entry could precipitate price erosion, with potential declines of 20-50%, influenced by market competition and biosimilar acceptance.
-
Continued pipeline development, line extensions, or combination therapies might sustain or increase prices by extending the product’s lifecycle and therapeutic relevance.
-
Implementation of value-based care and outcomes-based reimbursement models could constrain list prices but enhance net revenue through volume and value premiums.
Economic and Policy Considerations
Factors like healthcare policy reforms, price transparency initiatives, and international pricing controls could impose downward pressure, especially outside the U.S.
Competitive Analysis and Market Challenges
-
Market Entry Barriers: Patents, data exclusivity, and regulatory hurdles serve as significant barriers to new entrants, supporting high current prices.
-
Biosimilar Development: Entry of biosimilars could reduce prices but often face launch delays and market resistance, especially if originator maintains a strong patent portfolio.
-
Manufacturing and Innovation Costs: R&D, supply chain complexities, and compliance obligations sustain high price points for pioneering drugs over the patent life.
Pricing Strategy Insights
For stakeholders, understanding that market exclusivity, clinical value, and regulatory landscape largely dictate pricing is crucial. Future strategies should incorporate:
-
Early indication expansion to maximize revenue streams.
-
Engagement with payers to develop outcome-based reimbursement models.
-
Investment in biosimilar pipelines to mitigate future price erosion.
-
Monitoring policy developments for proactive pricing adjustments.
Key Takeaways
-
Market Potential: NDC 82667-0900 operates within a high-growth, high-demand segment, with significant potential for sustained premium pricing during exclusivity periods.
-
Pricing Stability & Erosion: Short-term prices are expected to remain stable or modestly increase; significant reductions may occur post-patent expiry with biosimilar entries.
-
Regulatory Impact: Regulatory approvals and reimbursement negotiations critically influence price trajectories.
-
Competitive Forces: Biosimilar entry and pipeline developments are primary factors governing long-term price declines.
-
Strategic Positioning: Investment in indication expansion and value-based contracts can optimize revenue amid competitive pressures.
Conclusion
NDC 82667-0900's market trajectory hinges on regulatory developments, patent protection, and competitive dynamics. While current prices are supported by market exclusivity and clinical value, long-term outlooks anticipate moderate declines aligned with biosimilar proliferation and healthcare policy shifts. Strategic positioning—incorporating indication expansion, outcome-based pricing, and pipeline development—is essential for maintaining favorable pricing and market share.
FAQs
Q1. What factors most strongly influence the pricing of NDC 82667-0900?
Regulatory approval scope, patent protection, clinical efficacy, competitive landscape, and payer negotiations primarily drive its price. Market exclusivity and clinical value enable premium pricing, while biosimilar entry can impose downward pressure.
Q2. How might biosimilar entry impact the price of NDC 82667-0900?
Biosimilars typically cause significant price reductions, ranging from 20% to over 70%, by introducing alternative treatments that create competitive pressure, benefitting payers and expanding access.
Q3. Are there opportunities for increasing revenue beyond the initial drug indication?
Yes. Expanding indications, developing combination therapies, and securing additional regulatory approvals can extend the product’s lifecycle and justify further price adjustments.
Q4. How do healthcare policies affect future pricing of this drug?
Policy initiatives promoting price transparency, value-based reimbursement, and price controls could constrain future price increases and foster more competitive pricing across markets.
Q5. What strategies should manufacturers consider to maintain profitability amid these market trends?
Diversifying indications, engaging in outcomes-based contracts, investing in pipeline development, and proactively managing patent protections are vital to sustain profitability in a dynamic pricing environment.
References
- Grand View Research, “Oncology Drugs Market Size & Trends,” 2022.
- IQVIA, “The Cost of Drug Development and Pricing Trends,” 2021.
More… ↓
